Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Bernard Silver, MD, is a Staff Member in the Department of Hematological Oncology and Blood Disorders at the Cleveland Clinic’s main campus. His specialty interests include Coagulation disorders (bleeding and thrombosis), including hemophilia, von Willebrand's disease, clotting factor deficiencies or inhibitors, thrombophilia (excess clotting), lupus anticoagulant or antiphospholipid syndrome, thrombocytopenia (ITP, TTP), and hemolytic anemia.
Dr. Silver is also an Associate Editor of the Cleveland Clinic Journal of Medicine, Course Director for Hematology at Cleveland Clinic Lerner College of Medicine and Program Director of bone marrow biopsies for Taussig Cancer Institute.
Dr. Silver earned his medical degree from the University of Michigan Medical School in Ann Arbor, Mich. He completed an internship and residency at Northwestern University Evanston Hospital in Evanston, IL. He also completed a fellowship at University of Michigan Health System in Ann Arbor.
He is board certified by the American Board of Internal Medicine with additional certifications in Hematology and Oncology.
He has been an invited lecturer and presenter on various aspects of coagulation, such as hemophilia, von Willebrand's disease and factor inhibitors as well as antiphospholipid syndrome and thrombophilia, among many others. Dr. Silver has also published a number of articles in peer-reviewed journals on topics related to anemia and adult thrombotic thrombocytopenic purpura.
Coagulation disorders, including hemophilia, von willebrand's disease, clotting factor deficiencies or inhibitors, thrombophilia, lupus anticoagulant or antiphospholipid syndrome, thrombocytopenia (ITP,TTP), hemolytic anemia.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland
Clinic's procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. The Cleveland Clinic requires its doctors to approve the public disclosures of their scientific collaborations with industry. As of 8/31/2014 the review process regarding Dr. Silver's disclosure had not been completed. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.